แนวคิดหลัก
A new blood test combining cell-free DNA fragmentomes and protein biomarkers demonstrates high sensitivity and specificity for detecting ovarian cancer, including early-stage disease.
บทคัดย่อ
The content discusses a new liquid biopsy test developed by Delfi Diagnostics that shows promising results for the early detection of ovarian cancer. The test uses machine learning to integrate cell-free DNA fragment patterns and concentrations of two ovarian cancer biomarkers (CA125 and HE4) to detect the presence and location of tumors.
The key highlights and insights from the content are:
- The test was evaluated in 134 women with ovarian cancer, 204 women without cancer, and 203 women with benign adnexal masses.
- The approach identified 69% of stage 1 cancers, 76% of stage 2, 85% of stage 3, and 100% of stage 4 at a specificity of over 99% and an area under the curve (AUC) of 0.97.
- The test identified 91% of high-grade serous ovarian cancers, which is the most common type of ovarian cancer.
- The AUC for distinguishing benign masses from cancer was 0.87, with 60% of ovarian cancers detected at a specificity of 95%.
- The researchers believe that in the preoperative setting, where lower specificity is acceptable, this approach may improve the management of adnexal masses.
- The findings are an initial analysis, and the researchers are working on validating the results on a larger scale in both average and high-risk women.
- If validated, the test could enable population-wide ovarian cancer screening, which could lead to earlier detection and improved outcomes for patients.
สถิติ
The test identified 69% of stage 1 ovarian cancers, 76% of stage 2, 85% of stage 3, and 100% of stage 4 at a specificity of over 99% and an area under the curve (AUC) of 0.97.
The test identified 91% of high-grade serous ovarian cancers, which is the most common type of ovarian cancer.
The AUC for distinguishing benign masses from cancer was 0.87, with 60% of ovarian cancers detected at a specificity of 95%.
คำพูด
"looks very sensitive for detecting ovarian cancer early"
"In the preoperative setting where lower specificity is acceptable, this approach may improve management of adnexal masses"
"If validated, the test 'could enable population-wide ovarian cancer screening'"